GlassScriptPhysician profile
Terri J Scott
NPI 1811085715
$2,095.16
in general payments reported to CMS, 2019-2025
30 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $24.90 · 2021: $17.28 · 2022: $563 · 2023: $251 · 2024: $564 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $340.23 | 2022-2025 | |
| Abbvie INC. | $330.71 | 2019-2022 | |
| Myovant Sciences INC. | $157.17 | 2022 | |
| Pfizer INC. | $153.67 | 2022-2024 | |
| Exeltis, USA INC. | $122.45 | 2024 | Slynd |
| Evofem Biosciences, INC. | $97.03 | 2023-2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $96.33 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $87.01 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $83.08 | 2024-2025 | Myfembree |
| Meditrina | $67.67 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.57 | 2019-2023 | |
| Avion Pharmaceuticals | $53.67 | 2019-2020 | |
| Smith+Nephew, INC. | $48.16 | 2022-2024 | Pico 7 |
| Dexcom, INC. | $45.72 | 2024-2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $35.88 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $30.78 | 2019 | |
| Millicent US INC | $30.00 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Shield Therapeutics INC | $24.37 | 2024 | |
| Astellas Pharma US INC | $24.13 | 2025 | Veozah |
| Ethicon US, LLC | $23.26 | 2024 | Dermabond Prineo, Stratafix, Ethicon |
| Tempus Ai, INC | $22.48 | 2025 | Xt Cdx |
| Mimedx Group, INC. | $20.27 | 2025 | |
| Biogen, INC. | $20.15 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $19.14 | 2023 | Thinprep 2000 Processor |
| Aspira Women'S Health INC | $17.99 | 2024 | Ova1 |
| Biotissue Holdings INC. | $17.77 | 2024 | |
| Roche Diagnostics Corporation | $16.81 | 2019 | |
| Merck Sharp & Dohme LLC | $16.69 | 2019 | |
| Duchesnay USA Incorporated | $14.49 | 2019 | |
| Minerva Surgical, INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.